Philippe Rougier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Philippe Rougier has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Luc Raoul
Department of Clinical Research, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France
2 shared publications P. Michel
2 shared publicationsA. Bardier
1 shared publicationA. Couvelard
1 shared publication- Alain Sauvanet
Department of Hepato‐Bilio‐Pancreatic Surgery and Liver Transplantation Beaujon Hospital, Assistance Publique‐Hôpitaux de Paris, Clichy, University Paris Cité Paris France
1 shared publication - Andrés Cervantes
INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
1 shared publication
Latest Publications
- Open Access
- 1 June 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_2) , ii1-ii4
The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona
Pancreatic ductal adenocarcinoma (PDAC) represents a significant cause of morbidity and mortality worldwide. With more than 80 000 deaths from pancreatic cancer predicted for 2013 in pancreatic cancer is the fourth leading cause of cancer death in Europe [1].
- 1 June 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_2) , ii1-ii4
Open AccessThe management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona
Pancreatic ductal adenocarcinoma (PDAC) represents a significant cause of morbidity and mortality worldwide. With more than 80 000 deaths from pancreatic cancer predicted for 2013 in pancreatic cancer is the fourth leading cause of cancer death in Europe [1].
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 4024
Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression.
4024 Background: In resected pancreatic adenocarcinoma (PA), gemcitabine was shown to improve both DFS and OS, equally to 5FU. In vitro, gemcitabine efficacy is linked to expression of the human equilibrative nucleoside transporter 1(hENT1), deoxycytidine kinase (dCK) and ribonucleotide reductase subunit1 (RRM1) proteins. This study evaluated association of these three proteins with efficacy of gemcitabine in resected PA. Methods: Patients with resected PA and no prior neoadjuvant therapy were accrued in 5 university hospitals. hENT1, dCK and RRM1 protein expression were semi-quantitatively assessed by immunohistochemistry using tissue microarray analysis and applying scoring systems as previously reported. The primary clinical end-point was overall survival (OS). The association of clinico-pathological parameters and protein expression with OS was evaluated by log-rank testing and Cox proportional regression. For statistical analysis, biomarkers expression was dichotomized as followed: hENT1 high vslow, dCK high vs low, RRM1 positive vs negative. Results: 434 patients with resected PA were analysed with a median OS of 30.4 months (95% CI: 26.0-34.8); 142 patients (32.7%) did not receive any adjuvant treatment; 243 (56%) were treated with an adjuvant gemcitabine-based therapy (Gem), and 49 (11.3%) with an adjuvant non gemcitabine-based therapy. In patients who did not received Gem (n=191), hENT1, RRM1 and dCK expression were not associated with OS in univariate and multivariate analysis. There was a significant interaction for OS between Gem and hENT1 (p=0.001), and Gem and dCK (p=0.001). In multivariate models adjusted for center, tumor grade, maximum tumor size, lymph nodes, and resection margins, Gem was associated with better OS in hENT1 high (n=163; HR: 0.44, 95%CI: 0.28-0.69, p<0.001) and in dCK high tumors (n=302; HR: 0.57, 95% CI:0.41-0.78, p=0.001). By contrast, in dCK low (n= 114, p=0.73) and in hENT1 low (n=249, p=0.66) tumors, patients derived no benefit from gemcitabine. Conclusions: In this multicenter study, hENT1 and dCK high expressions may predict benefit from gem-based chemotherapy after curative-intent surgery in PA.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 4024
Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression.
4024 Background: In resected pancreatic adenocarcinoma (PA), gemcitabine was shown to improve both DFS and OS, equally to 5FU. In vitro, gemcitabine efficacy is linked to expression of the human equilibrative nucleoside transporter 1(hENT1), deoxycytidine kinase (dCK) and ribonucleotide reductase subunit1 (RRM1) proteins. This study evaluated association of these three proteins with efficacy of gemcitabine in resected PA. Methods: Patients with resected PA and no prior neoadjuvant therapy were accrued in 5 university hospitals. hENT1, dCK and RRM1 protein expression were semi-quantitatively assessed by immunohistochemistry using tissue microarray analysis and applying scoring systems as previously reported. The primary clinical end-point was overall survival (OS). The association of clinico-pathological parameters and protein expression with OS was evaluated by log-rank testing and Cox proportional regression. For statistical analysis, biomarkers expression was dichotomized as followed: hENT1 high vslow, dCK high vs low, RRM1 positive vs negative. Results: 434 patients with resected PA were analysed with a median OS of 30.4 months (95% CI: 26.0-34.8); 142 patients (32.7%) did not receive any adjuvant treatment; 243 (56%) were treated with an adjuvant gemcitabine-based therapy (Gem), and 49 (11.3%) with an adjuvant non gemcitabine-based therapy. In patients who did not received Gem (n=191), hENT1, RRM1 and dCK expression were not associated with OS in univariate and multivariate analysis. There was a significant interaction for OS between Gem and hENT1 (p=0.001), and Gem and dCK (p=0.001). In multivariate models adjusted for center, tumor grade, maximum tumor size, lymph nodes, and resection margins, Gem was associated with better OS in hENT1 high (n=163; HR: 0.44, 95%CI: 0.28-0.69, p<0.001) and in dCK high tumors (n=302; HR: 0.57, 95% CI:0.41-0.78, p=0.001). By contrast, in dCK low (n= 114, p=0.73) and in hENT1 low (n=249, p=0.66) tumors, patients derived no benefit from gemcitabine. Conclusions: In this multicenter study, hENT1 and dCK high expressions may predict benefit from gem-based chemotherapy after curative-intent surgery in PA.
- 23 November 2010
- Published by Lavoisier in Côlon & Rectum
- Vol. 4 (4) , 241-242
Les hépatogastroentérologues et la chimiothérapie en cancérologie digestive
- 23 November 2010
- Published by Lavoisier in Côlon & Rectum
- Vol. 4 (4) , 241-242
Les hépatogastroentérologues et la chimiothérapie en cancérologie digestive
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e16503
The role of French gastroenterologists (GE) in digestive oncology: Results of a national survey (FFCD, FSMAD, AFEF, ANGH, CREGG, SFED, SNFGE).
E16503 Background: A collaborative work between medical oncologists and gastroenterologists (GEs) seems to be necessary in digestive oncology. So each partner gives his specific knowledge to the patients. The aim of this survey was to analyze the role of French GEs in the care of patients with digestive cancers. Methods: Between October 2007 and March 2008, 3,714 anonymous questionnaires were sent to French GEs, determining their profile, use of chemotherapy and involvement in therapeutic trials. Statistical analysis was carried out in the FFCD data center. Results: We collected 1,663 responses (45%). Responders were from private practices (48%), general hospitals (GH) (27%) and academic hospitals (AH) (15%). Among the responders, 24% of the GEs from private practice, 40% from GH, and 55% from AH said they devoted more than 30% of time to digestive oncology. Most of the GEs (89%) participated weekly or twice weekly in multidisciplinary staff meetings. Indications for chemotherapy were identified by 886 GEs (53%). Chemotherapy prescriptions were carried out by 591 GEs, 364 GEs (22%) prescribed all courses of chemotherapy that they carried out, whereas 227 (14 %) prescribed only some of the courses. Involvement in clinical trials was reported by 476 GEs. Most of these trials took place in Centres de Lutte Contre le Cancer (87%) or AH (74%); a smaller proportion involved GH (28%) and private clinics (13%). The geographic analysis including the prevalence of colonic cancers in France showed that the proportion of GEs prescribing chemotherapy was higher in regions with fewer oncologists (oncologists + GE-oncologists) per inhabitant with colonic cancer. Conclusions: Digestive oncology now accounts for a major part of the activity of many French GEs. The GEs and oncologists seem to play complementary roles in chemotherapy, with a special involvement of the GEs in areas poor in oncologists. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e16503
The role of French gastroenterologists (GE) in digestive oncology: Results of a national survey (FFCD, FSMAD, AFEF, ANGH, CREGG, SFED, SNFGE).
E16503 Background: A collaborative work between medical oncologists and gastroenterologists (GEs) seems to be necessary in digestive oncology. So each partner gives his specific knowledge to the patients. The aim of this survey was to analyze the role of French GEs in the care of patients with digestive cancers. Methods: Between October 2007 and March 2008, 3,714 anonymous questionnaires were sent to French GEs, determining their profile, use of chemotherapy and involvement in therapeutic trials. Statistical analysis was carried out in the FFCD data center. Results: We collected 1,663 responses (45%). Responders were from private practices (48%), general hospitals (GH) (27%) and academic hospitals (AH) (15%). Among the responders, 24% of the GEs from private practice, 40% from GH, and 55% from AH said they devoted more than 30% of time to digestive oncology. Most of the GEs (89%) participated weekly or twice weekly in multidisciplinary staff meetings. Indications for chemotherapy were identified by 886 GEs (53%). Chemotherapy prescriptions were carried out by 591 GEs, 364 GEs (22%) prescribed all courses of chemotherapy that they carried out, whereas 227 (14 %) prescribed only some of the courses. Involvement in clinical trials was reported by 476 GEs. Most of these trials took place in Centres de Lutte Contre le Cancer (87%) or AH (74%); a smaller proportion involved GH (28%) and private clinics (13%). The geographic analysis including the prevalence of colonic cancers in France showed that the proportion of GEs prescribing chemotherapy was higher in regions with fewer oncologists (oncologists + GE-oncologists) per inhabitant with colonic cancer. Conclusions: Digestive oncology now accounts for a major part of the activity of many French GEs. The GEs and oncologists seem to play complementary roles in chemotherapy, with a special involvement of the GEs in areas poor in oncologists. No significant financial relationships to disclose.
- Open Access
- 14 April 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 112
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
Background: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. Methods: The 5-FU dose was selected on the basis of dose-limiting toxicities (DLTs) during part I of the study. Patients received cetuximab (400 mg/m2 initial dose and 250 mg/m2/week thereafter) and every 2 weeks irinotecan (180 mg/m2), FA (400 mg/m2) and 5-FU (either low dose [LD], 300 mg/m2 bolus plus 2,000 mg/m2 46-hour infusion, n = 7; or, high-dose [HD], 400 mg/m2 bolus plus 2,400 mg/m2; n = 45). Results: Only two DLTs occurred in the HD group, and HD 5-FU was selected for use in part II. Apart from rash, commonly observed grade 3/4 adverse events such as leucopenia, diarrhoea, vomiting and asthenia occurred within the expected range for FOLFIRI. Among 52 patients, the overall response rate was 48%. Median progression-free survival (PFS) was 8.6 months (counting all reported progressions) and the median overall survival was 22.4 months. Treatment facilitated the resection of initially unresectable metastases in fourteen patients (27%): of these, 10 patients (71%) had no residual tumour after surgery, and these resections hindered the estimation of PFS. Conclusion: The combination of cetuximab and FOLFIRI was active and well tolerated in this setting. Initially unresectable metastases became resectable in one-quarter of patients, with a high number of complete resections, and these promising results formed the basis for the investigation of FOLFIRI with and without cetuximab in the phase III CRYSTAL trial.
- 14 April 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 112
Open AccessCetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
Background: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. Methods: The 5-FU dose was selected on the basis of dose-limiting toxicities (DLTs) during part I of the study. Patients received cetuximab (400 mg/m2 initial dose and 250 mg/m2/week thereafter) and every 2 weeks irinotecan (180 mg/m2), FA (400 mg/m2) and 5-FU (either low dose [LD], 300 mg/m2 bolus plus 2,000 mg/m2 46-hour infusion, n = 7; or, high-dose [HD], 400 mg/m2 bolus plus 2,400 mg/m2; n = 45). Results: Only two DLTs occurred in the HD group, and HD 5-FU was selected for use in part II. Apart from rash, commonly observed grade 3/4 adverse events such as leucopenia, diarrhoea, vomiting and asthenia occurred within the expected range for FOLFIRI. Among 52 patients, the overall response rate was 48%. Median progression-free survival (PFS) was 8.6 months (counting all reported progressions) and the median overall survival was 22.4 months. Treatment facilitated the resection of initially unresectable metastases in fourteen patients (27%): of these, 10 patients (71%) had no residual tumour after surgery, and these resections hindered the estimation of PFS. Conclusion: The combination of cetuximab and FOLFIRI was active and well tolerated in this setting. Initially unresectable metastases became resectable in one-quarter of patients, with a high number of complete resections, and these promising results formed the basis for the investigation of FOLFIRI with and without cetuximab in the phase III CRYSTAL trial.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 3513
Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA
3513 Background: Cetuximab is an IgG1 monoclonal antibody targeting the EGFR. In irinotecan-refractory metastatic CRC and in first-line therapy trials cetuximab has shown to be active (ASCO 2002, 2003). This phase II trial evaluates the safety and efficacy of cetuximab combined with a FOLFIRI regimen as first-line treatment for pts with EGFR-expressing metastatic CRC. Methods: Cetuximab was given at an initial dose of 400 mg/m2, then 250 mg/m2 i.v. weekly. FOLFIRI was administered every 2 weeks: Irinotecan 180 mg/m2, FA 400 mg/m2 and 5-FU 300 mg/m2 bolus plus infusion of 2,000 mg/m2/46h (low dose group, LD) or 400 mg/m2 bolus plus infusion of 2,400 mg/m2/46h (high dose group, HD). Dose limiting toxicity (DLT) was defined as neutropenia/leukopenia, thrombopenia, alk. phosphatase, bilirubin, ASAT, ALAT or skin toxicity > grade (Gd) 3; neutropenia with fever/infection, anemia, diarrhea, mucositis, creatinine, or any treatment-related organ toxicity > Gd 2 during the first 3 cycles. Results: The first 23 pts were evaluated for DLT, 10 in LD, 13 in HD group. Median age was 66 years (36–76) and median KPS was 90 (60–100). No DLT occurred in the LD group, but 3 DLT in the HD (diarrhea Gd 3, allergy Gd 3, neutropenia Gd 4). 22 pts were evaluable for efficacy: PR 10 (46%, C.I., 25–66%), SD 9 (41%), PD 3 (14%). 7 pts underwent secondary surgery of metastases. So far, median TTP was 10.9 months. To allow a better estimate of safety and efficacy for a planned phase III trial, further 29 patients were enrolled in the HD group that has demonstrated an acceptable safety profile. Safety analysis in the HD group was based on 42 pts. The most frequent grade 3/4 adverse events were diarrhea 14.3%, neutropenia 11.9%, rash, 11.9%, and nausea/vomiting 9.5%. Frequency of acne-like rash of grade 1/2/3/4 was 28.6/26.2/4.8/0 %. 5 pts were still on treatment at the time of abstract submission. Conclusion: The combination of cetuximab with FOLFIRI is safe and feasible in pts with EGFR-expressing metastatic CRC and is clearly active.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 3513
Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA
3513 Background: Cetuximab is an IgG1 monoclonal antibody targeting the EGFR. In irinotecan-refractory metastatic CRC and in first-line therapy trials cetuximab has shown to be active (ASCO 2002, 2003). This phase II trial evaluates the safety and efficacy of cetuximab combined with a FOLFIRI regimen as first-line treatment for pts with EGFR-expressing metastatic CRC. Methods: Cetuximab was given at an initial dose of 400 mg/m2, then 250 mg/m2 i.v. weekly. FOLFIRI was administered every 2 weeks: Irinotecan 180 mg/m2, FA 400 mg/m2 and 5-FU 300 mg/m2 bolus plus infusion of 2,000 mg/m2/46h (low dose group, LD) or 400 mg/m2 bolus plus infusion of 2,400 mg/m2/46h (high dose group, HD). Dose limiting toxicity (DLT) was defined as neutropenia/leukopenia, thrombopenia, alk. phosphatase, bilirubin, ASAT, ALAT or skin toxicity > grade (Gd) 3; neutropenia with fever/infection, anemia, diarrhea, mucositis, creatinine, or any treatment-related organ toxicity > Gd 2 during the first 3 cycles. Results: The first 23 pts were evaluated for DLT, 10 in LD, 13 in HD group. Median age was 66 years (36–76) and median KPS was 90 (60–100). No DLT occurred in the LD group, but 3 DLT in the HD (diarrhea Gd 3, allergy Gd 3, neutropenia Gd 4). 22 pts were evaluable for efficacy: PR 10 (46%, C.I., 25–66%), SD 9 (41%), PD 3 (14%). 7 pts underwent secondary surgery of metastases. So far, median TTP was 10.9 months. To allow a better estimate of safety and efficacy for a planned phase III trial, further 29 patients were enrolled in the HD group that has demonstrated an acceptable safety profile. Safety analysis in the HD group was based on 42 pts. The most frequent grade 3/4 adverse events were diarrhea 14.3%, neutropenia 11.9%, rash, 11.9%, and nausea/vomiting 9.5%. Frequency of acne-like rash of grade 1/2/3/4 was 28.6/26.2/4.8/0 %. 5 pts were still on treatment at the time of abstract submission. Conclusion: The combination of cetuximab with FOLFIRI is safe and feasible in pts with EGFR-expressing metastatic CRC and is clearly active.